Ikarian Capital’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Ikarian Capital’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-448,101	Closed	-$148K	–	169
2023 Q1	$148K	Hold	448,101	–	–	0.03%	109
2022 Q4	$323K	Hold	448,101	–	–	0.08%	67
2022 Q3	$537K	Sell	448,101 -75,247	-14%	-$95.9K	0.11%	82
2022 Q2	$617K	Hold	523,348	–	–	0.11%	95
2022 Q1	$1.13M	Buy	523,348 +26,592	+5%	+$43.2K	0.15%	93
2021 Q4	$739K	Hold	496,756	–	–	0.11%	113
2021 Q3	$1.45M	Sell	496,756 -3,244	-0.6%	-$9.89K	0.1%	142
2021 Q2	$1.65M	Hold	500,000	–	–	0.13%	141
2021 Q1	$1.88M	Hold	500,000	–	–	0.06%	205
2020 Q4	$1.76M	Buy	+500,000	New	+$2.11M	0.08%	161

Other funds holding BLCM

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

PGAM

Princeton Global Asset Management Princeton, New Jersey $698M AUM 31.09% 1-Year Est. Return

Ikarian Capital's BLCM Position: Q2 2023 in Review

Ikarian Capital sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2023, closing a stake of 448,101 shares — an estimated $148K sold.

Ikarian Capital first reported a position in BLCM in Q4 2020 and held it in 10 quarters. The position peaked at $1.88M in Q1 2021. 4 funds tracked by Wall St. Rank hold BLCM as of Q2 2023.

Ikarian Capital reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Ikarian Capital sold 448,101 Bellicum Pharmaceuticals, Inc. shares in Q2 2023, an estimated $148K.
Ikarian Capital first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2020 and held it in 10 quarters.
Ikarian Capital's Bellicum Pharmaceuticals, Inc. position peaked at $1.88M in Q1 2021.
4 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2023.

Based on Ikarian Capital's 13F filing for Q2 2023, filed 14 Aug 2023.